After 6years of intraperitoneal insulin administration IGF-I concentrations in T1DM patients are at low-normal level.
2015 (English)In: Growth Hormone & IGF Research, ISSN 1096-6374, E-ISSN 1532-2238, Vol. 25, no 6, 316-319 p.Article in journal (Refereed) Published
OBJECTIVE: Low concentrations of insulin-like growth factor-I (IGFI) have been reported in type 1 diabetes mellitus (T1DM), suggested to be due to low insulin concentrations in the portal vein. The aim was to describe the long-term course of IGFI concentrations among T1DM subjects treated with continuous intraperitoneal (IP) insulin infusion (CIPII).
DESIGN: Nineteen patients that participated in a randomized cross-over trial comparing CIPII and subcutaneous (SC) insulin therapy in 2006 were followed until 2012. IGF-I measurements were performed at the start of the 2006 study, after the 6month SC- and CIPII treatment phase in 2006 and during CIPII therapy in 2012. Z-scores were calculated to compare the IGF-I concentrations with age-specific normative range values of a non-DM reference population.
RESULTS: In 2012, IGF-I Z-scores (-0.7; 95% confidence interval -1.3, -0.2) were significantly higher than at the start of the 2006 study (-2.5; -3.3, -1.8), the end of the SC (-2.0; -2.6, -1.5) and CIPII (-1.6; -2.1, -1.0) treatment phase with a mean difference of: 1.8 (0.9, 2.7), 1.3 (0.5, 2.1) and 0.8 (0.1, 1.6), respectively.
CONCLUSION: After 6years of treatment with CIPII, IGF-I concentrations among T1DM patients increased to a level that is higher than during prior SC insulin treatment and is in the lower normal range compared to a non-DM reference population. The results of this study suggest that long-term IP insulin administration influences the IGF system in T1DM.
Place, publisher, year, edition, pages
2015. Vol. 25, no 6, 316-319 p.
IGF-I; Intraperitoneal insulin; Type 1 diabetes mellitus
Endocrinology and Diabetes Physiology
IdentifiersURN: urn:nbn:se:liu:diva-124061DOI: 10.1016/j.ghir.2015.08.007ISI: 000366962800009PubMedID: 26336814OAI: oai:DiVA.org:liu-124061DiVA: diva2:895648
Funding agencies: Medical Research Council of Southeast Sweden (FORSS); Stichting Zwols Wetenschapsfonds Isala Klinieken (ZWIK)2016-01-192016-01-192016-04-12